TEVA: A Pharmaceutical Stock to Watch Right Now

teve pharmaceutical stock buy investing analysis price chart image

Every week, I am invited on Business First AM with Angela Miles to discuss the market and give a stock pick.

This week, I covered TEVA, a stock I have talked about a few times and one, full disclosure, we are positioned in.

First, about the company:

Teva Pharmaceuticals is an international pharmaceutical company headquartered in Israel.

Sign up for our FREE newsletter
and receive our best trading ideas and research

Founded in 1901, Teva is one of the world’s largest generic drug manufacturers.

The company specializes in the development, production, and marketing of a wide range of generic and specialty pharmaceutical products.

Teva’s generic drugs are typically less expensive alternatives to brand-name medications, which can help make healthcare more affordable for patients and healthcare systems. 

In addition to generics, Teva also develops and manufactures specialty pharmaceuticals, including drugs for conditions such as multiple sclerosis, respiratory diseases, and central nervous system disorders.

Challenges legally resolved:

The company has faced its share of challenges and controversies, including legal disputes related to generic drug pricing and allegations of anticompetitive behavior. 

However, one big development TEVA reached a deferred prosecution agreement (DPA) with the U.S. Department of Justice (DOJ) to settle the criminal price-fixing charges brought against Teva in 2020. Teva will pay a fine of $225 million over five years, with $22.5 million due each year from 2024 through 2027, and $135 million due in 2028.

The bad news is that this will impact on their bottom line.

The good news is that the case is settled and done with.

The chart is fascinating. 

The resistance at 10.00 is clear on the daily chart.

TEVA is one of the few instruments that has handily cleared its July 6-month calendar range high (green horizontal line).

The 50 daily moving average is about to cross or golden cross the 200-DMA and enter a bullish phase.

Since the earnings gap early August, price has consolidated.

Our Leadership indicator show TEVA beginning to outperform the SPY.

Our Real Motion indicator already in a bullish phase is not quite at the early August high in momentum so that is why we are waiting for a clearance of the price resistance at 10.00 

Stock Market ETFs Trading Analysis & Summary:

S&P 500 (SPY) 440 support 458 resistance

Russell 2000 (IWM) 185 pivotal 

Dow (DIA) 347 pivotal 

Nasdaq (QQQ) 363 support and over 375 looks better

Regional banks (KRE) Another modern family member struggling here under 44

Semiconductors (SMH) 150-161 range to watch

Transportation (IYT) Needs to get back over 247 to look healthier 

Biotechnology (IBB) Compression between 124-130

Retail (XRT) 62.90 the July calendar range low broke down-along with IYT-2 negative signs

Twitter: @marketminute

The author may have a position in mentioned securities at the time of publication. Any opinions expressed herein are solely those of the author and do not represent the views or opinions of any other person or entity.